4.8 Article

RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition

Journal

ONCOGENE
Volume 35, Issue 14, Pages 1760-1769

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2015.240

Keywords

-

Funding

  1. INSERM (Institut National de la Sante et de la Recherche Medicale)
  2. Groupe de Recherche Institut Claudius Regaud
  3. Foundation Recherche et Innovation Therapeutique en Cancerologie
  4. INCa (Institut National du Cancer) France

Ask authors/readers for more resources

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, which is mainly due to its high risk of metastatic dissemination. One critical point of this process is the ability of cancer cells to detach from the primary tumor and migrate through the extracellular matrix; however, the underlying molecular mechanisms are not yet fully understood. In the present study, we identified the small GTPase RhoB as a key regulator of bronchial cell morphology in a three-dimensional (3D) matrix. RhoB loss, which is frequently observed during lung cancer progression, induced an epithelial-mesenchymal transition (EMT) characterized by an increased proportion of invasive elongated cells in 3D. The process was mediated by Slug induction and E-cadherin repression. In addition, downregulation of RhoB induced Akt1 activation, which in turn activated Rac1 through the guanine-exchange factor Trio to control cell shape rearrangement. Further, we provide evidence that RhoB interacted with and positively regulates phosphatase PP2A through the recruitment of its regulatory subunit B55, which was found to be crucial for Akt dephosphorylation. B55 inhibition completely suppressed RhoB-mediated PP2A regulation. Finally, we show that PP2A inactivation, by targeting either its catalytic or its regulatory B55 subunit, completely reversed RhoB-dependent morphological changes and also fully prevented the ability of RhoB to decrease the invasiveness of bronchial cells. Altogether, these results highlight a novel signaling axis and describe new molecular mechanisms that could explain the tumor suppressor role of RhoB in lung cancer. Therefore, we propose that RhoB could be responsible for early metastatic prevention by inhibiting the EMT-derived invasiveness of lung cells through the control of PP2A activity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Meeting Abstract Oncology

Oligometastatic breast cancer incidence and clinical presentation at diagnosis: About 131 cases

J. L. Lacaze, C. Chira, G. Glemarec, R. Aziza, E. De Maio, F. Izar, E. Jouve, C. Massabeau, A. Pradines, G. Selmes, M. Ung, S. Zerdoud, F. Dalenc

ANNALS OF ONCOLOGY (2020)

Article Pathology

Minimal Residual Disease Monitoring Using a 3′ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma ddPCR, an Attractive Alternative Method to Real-Time Quantitative PCR

Cathy Quelen, David Grand, Emeline Sarot, Laurence Brugieres, David Sibon, Anne Pradines, Camille Laurent, Pierre Brousset, Laurence Lamant

Summary: In ALK-positive anaplastic large-cell lymphomas, real-time quantitative PCR can identify high-risk patients, but the current technique designed for patients with the most common NPM1-ALK translocation has reproducibility issues among different laboratories.

JOURNAL OF MOLECULAR DIAGNOSTICS (2021)

Article Oncology

Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel

David Gandara, Martin Reck, Denis Moro-Sibilot, Julien Mazieres, Shirish Gadgeel, Stefanie Morris, Andres Cardona, Diana Mendus, Marcus Ballinger, Achim Rittmeyer, Solange Peters

Summary: The study aimed to develop criteria for fast progression (FP) by analyzing data from the randomized phase III OAK study, showing that FP rates were similar with atezolizumab and docetaxel and suggesting that FP may not be unique to checkpoint inhibitors, although the underlying mechanisms may differ from those of chemotherapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Review Oncology

Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges

Bryan Ulrich, Anne Pradines, Julien Mazieres, Nicolas Guibert

Summary: Circulating tumor DNA is a novel biomarker that shows potential in predicting cancer relapse and guiding adjuvant therapies. In patients with localized disease, ctDNA kinetics is considered a highly sensitive and specific marker for relapse. Further research is needed to explore the full potential of ctDNA as a tool for personalized treatment in non-small-cell lung cancer.

CANCERS (2021)

Article Oncology

Diagnosis, biology and epidemiology of oligometastatic breast cancer

Jean-Louis Lacaze, Richard Aziza, Ciprian Chira, Eleonora De Maio, Francoise Izar, Eva Jouve, Carole Massabeau, Anne Pradines, Gabrielle Selmes, Mony Ung, Slimane Zerdoud, Florence Dalenc

Summary: Oligometastatic breast cancer (OMBC) lacks a standardized treatment strategy, with limited information provided by existing literature. Research on OMBC biological characteristics suggests a focus on circulating tumor cell counts, as well as development of studies on microRNAs, circulating tumor DNA, and genomic alterations.

BREAST (2021)

Article Oncology

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Xiuning Le, Hiroshi Sakai, Enriqueta Felip, Remi Veillon, Marina Chiara Garassino, Jo Raskin, Alexis B. Cortot, Santiago Viteri, Julien Mazieres, Egbert F. Smit, Michael Thomas, Wade T. Iams, Byoung Chul Cho, Hye Ryun Kim, James Chih-Hsin Yang, Yuh-Min Chen, Jyoti D. Patel, Christine M. Bestvina, Keunchil Park, Frank Griesinger, Melissa Johnson, Maya Gottfried, Christian Britschgi, John Heymach, Elif Sikoglu, Karin Berghoff, Karl-Maria Schumacher, Rolf Bruns, Gordon Otto, Paul K. Paik

Summary: Tepotinib demonstrated durable clinical activity in patients with METex14 skipping non-small cell lung cancer and consistent efficacy and manageable safety profile across different subgroups.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

Egbert F. Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M. Tho, Xiuning Le, Julien Mazieres, How S. Hin, Masahire Morise, Viola W. Zhu, Daniel Tan, Kristina H. Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M. Schumacher, Niki Karachaliou, Yi-Long Wu

Summary: Combining osimertinib with MET inhibitor like tepotinib could potentially overcome resistance driven by MET amplification in NSCLC patients, and the ongoing study INSIGHT 2 aims to evaluate the efficacy and safety of this combination therapy for patients with acquired resistance to osimertinib due to MET amplification.

FUTURE ONCOLOGY (2022)

Article Oncology

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial

Julien Mazieres, Claire Lafitte, Charles Ricordel, Laurent Greillier, Elodie Negre, Gerard Zalcman, Charlotte Domblides, Jeannick Madelaine, Jaafar Bennouna, Celine Mascaux, Denis Moro-Sibilot, Francois Pinquie, Alexis B. Cortot, Josiane Otto, Jacques Cadranel, Alexandra Langlais, Franck Morin, Virginie Westeel, Benjamin Besse

Summary: This study evaluated the efficacy of a triple therapy with HER2-targeted antibodies and docetaxel in HER2-mutated NSCLC patients, demonstrating feasibility and effectiveness of this approach, highlighting the potential benefit of HER2 antibody-based strategy in this subset of patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Biochemistry & Molecular Biology

Mycobacteria-host interactions in human bronchiolar airway organoids

Nino Iakobachvili, Stephen Adonai Leon-Icaza, Kevin Knoops, Norman Sachs, Serge Mazeres, Roxane Simeone, Antonio Peixoto, Celia Bernard, Marlene Murris-Espin, Julien Mazieres, Kaymeuang Cam, Christian Chalut, Christophe Guilhot, Carmen Lopez-Iglesias, Raimond B. G. Ravelli, Olivier Neyrolles, Etienne Meunier, Geanncarlo Lugo-Villarino, Hans Clevers, Celine Cougoule, Peter J. Peters

Summary: The study found that Mycobacterium tuberculosis and Mycobacterium abscessus mainly exist as extracellular bacteria in human airway organoids, infecting epithelial cells with low efficiency. The organoids respond to infection by modulating cytokine, antimicrobial peptide, and mucin gene expression. Adult stem cell-derived airway organoids can be used to elucidate early events of mycobacterial infection in human settings.

MOLECULAR MICROBIOLOGY (2022)

Article Biochemistry & Molecular Biology

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, Valerio Iebba, Gerard Zalcman, Sylvie Friard, Julien Mazieres, Clarisse Audigier-Valette, Denis Moro-Sibilot, Francois Goldwasser, Carolina Alves Costa Silva, Safae Terrisse, Melodie Bonvalet, Arnaud Scherpereel, Herve Pegliasco, Corentin Richard, Francois Ghiringhelli, Arielle Elkrief, Antoine Desilets, Felix Blanc-Durand, Fabio Cumbo, Aitor Blanco, Romain Boidot, Sandy Chevrier, Romain Daillere, Guido Kroemer, Laurie Alla, Nicolas Pons, Emmanuelle Le Chatelier, Nathalie Galleron, Hugo Roume, Agathe Dubuisson, Nicole Bouchard, Meriem Messaoudene, Damien Drubay, Eric Deutsch, Fabrice Barlesi, David Planchard, Nicola Segata, Stephanie Martinez, Laurence Zitvogel, Jean-Charles Soria, Benjamin Besse

Summary: In addition to PD-L1 expression, biomarkers for predicting the response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. This study found that fecal Akkermansia muciniphila (Akk) was associated with clinical benefit of ICI treatment in NSCLC patients, independent of PD-L1 expression and other factors. The relative abundance of Akk in the gut microbiome may serve as a potential biomarker for patient stratification.

NATURE MEDICINE (2022)

Review Oncology

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer

Celia Delahaye, Sarah Figarol, Anne Pradines, Gilles Favre, Julien Mazieres, Olivier Calvayrac

Summary: The article discusses the benefits and limitations of more effective treatments for lung cancer patients, as well as the emergence of resistance. It emphasizes the importance of understanding the mechanisms underlying DTP survival for developing therapeutic strategies.

CANCERS (2022)

Article Oncology

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

Marie Wislez, Julien Mazieres, Armelle Lavole, Gerard Zalcman, Olivier Carre, Thomas Egenod, Raffaele Caliandro, Catherine Dubos-Arvis, Gaelle Jeannin, Olivier Molinier, Marie-Ange Massiani, Alexandra Langlais, Franck Morin, Francoise Le Pimpec Barthes, Laurent Brouchet, Jalal Assouad, Bernard Milleron, Diane Damotte, Martine Antoine, Virginie Westeel

Summary: This study assessed the feasibility of neoadjuvant durvalumab for early-stage resectable non-small-cell lung cancer. The results showed that this treatment approach resulted in a high complete resection rate and some pathological response. However, the unexpectedly high postoperative mortality rate led to the premature termination of the study.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

Pembrolizumab Plus Chemotherapy in Squamous Non Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Silvia Novello, Dariusz M. Kowalski, Alexander Luft, Mahmut Gumus, David Vicente, Julien Mazieres, Jeronimo Rodriguez-Cid, Ali Tafreshi, Ying Cheng, Ki Hyeong Lee, Alexander Golf, Shunichi Sugawara, Andrew G. Robinson, Balazs Halmos, Erin Jensen, Paul Schwarzenberger, M. Catherine Pietanza, Luis Paz-Ares

Summary: This study provides five-year efficacy and safety outcomes for the treatment of previously untreated metastatic squamous non-small cell lung cancer patients. The results show that pembrolizumab plus chemotherapy significantly improves overall survival and progression-free survival compared to placebo plus chemotherapy. This study demonstrates that pembrolizumab plus chemotherapy is a first-line treatment option for metastatic squamous NSCLC regardless of programmed death ligand 1 expression.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Review Oncology

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes

Julien Mazieres, Helene Vioix, Boris M. Pfeiffer, Rhiannon I. Campden, Zhiyuan Chen, Bart Heeg, Alexis B. Cortot

Summary: METex14 skipping is a rare oncogenic driver in non-small-cell lung cancer and targeted therapy with MET tyrosine kinase inhibitors has been approved for its treatment. A systematic literature review found that the median frequency of METex14 skipping was 2.0% in unselected NSCLC patients and 2.4% in adenocarcinoma or nonsquamous subgroups. MET TKIs appeared to have higher efficacy outcomes for METex14 skipping NSCLC patients, but direct comparisons with chemotherapy or immunotherapy regimens were lacking.

CLINICAL LUNG CANCER (2023)

Meeting Abstract Oncology

Characterization of ESR1 mutations at metastatic relapse and outcome under first line aromatase inhibitor and palbociclib in the PADA-1 trial.

Anne Pradines, Celine Callens, Aurelia Doussine, Ivan Bieche, Jerome Lemonnier, Marjorie Mauduit, Thomas Bachelot, Florence Dalenc, Alain Lortholary, Barbara Pistilli, Thibault De la Motte Rouge, Renaud Sabatier, Jean-Marc Ferrero, Sylvain Ladoire, Frederique Berger, Francois-Clement Bidard

CANCER RESEARCH (2021)

No Data Available